🔗 Share this article World Health Organization Sounds Alert Over Critical Scarcity of Weight-Loss Jabs Under a tenth of individuals who could benefit from weight-loss injections such as Wegovy can access them, states the World Health Organization as it issues its first guidance on the drugs. With more than one billion people worldwide currently obese, it is advocating for more widespread and fairer availability to GLP-1 medication. Per forecasts, more than two billion could be obese by 2030 if no action is taken. "The latest guidance affirms that excess weight is a lifelong illness that can be managed with comprehensive and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and supply-chain constraints are major hurdles to universal access to the treatments that can help people shift significant body mass, notes the organization. Weight-Loss Drug Supply Crisis Even under the present best projected outlook, the production of such drugs might only reach approximately 100 million people – less than 10% of eligible patients, per the health organization. The advice urges governments and firms to widen availability, through measures such as patent sharing. Exclusive production rights on the active ingredient – the core component of a leading brand – is scheduled to end in a number of nations in 2026. How Obesity Drugs Function GLP-1 drugs mimick a biological compound to reduce digestion speed, curb appetite and enhance feelings of fullness so users eat less. Individuals commonly see weight reduction in the initial weeks of beginning the regular doses. Studies points to patients may put most of the weight back on within a year of stopping the drug, because their typical food cravings return. Being above a healthy weight increases your risk for contracting diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and certain cancers. Excess weight impacts people in all nations and was linked to millions of fatalities worldwide in 2024, per the health agency.
Under a tenth of individuals who could benefit from weight-loss injections such as Wegovy can access them, states the World Health Organization as it issues its first guidance on the drugs. With more than one billion people worldwide currently obese, it is advocating for more widespread and fairer availability to GLP-1 medication. Per forecasts, more than two billion could be obese by 2030 if no action is taken. "The latest guidance affirms that excess weight is a lifelong illness that can be managed with comprehensive and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and supply-chain constraints are major hurdles to universal access to the treatments that can help people shift significant body mass, notes the organization. Weight-Loss Drug Supply Crisis Even under the present best projected outlook, the production of such drugs might only reach approximately 100 million people – less than 10% of eligible patients, per the health organization. The advice urges governments and firms to widen availability, through measures such as patent sharing. Exclusive production rights on the active ingredient – the core component of a leading brand – is scheduled to end in a number of nations in 2026. How Obesity Drugs Function GLP-1 drugs mimick a biological compound to reduce digestion speed, curb appetite and enhance feelings of fullness so users eat less. Individuals commonly see weight reduction in the initial weeks of beginning the regular doses. Studies points to patients may put most of the weight back on within a year of stopping the drug, because their typical food cravings return. Being above a healthy weight increases your risk for contracting diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and certain cancers. Excess weight impacts people in all nations and was linked to millions of fatalities worldwide in 2024, per the health agency.